Lanean...
Neoadjuvant checkpoint blockade for cancer immunotherapy
Cancer immunotherapies that target the programmed cell death 1 (PD-1):programmed death-ligand1 (PD-L1) immune checkpoint pathway have ushered in the modern oncology era. Drugs that block PD-1 or PD-L1 facilitate endogenous antitumor immunity and, because of their broad activity spectrum, have been r...
Gorde:
| Argitaratua izan da: | Science |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7789854/ https://ncbi.nlm.nih.gov/pubmed/32001626 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/science.aax0182 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|